TY - JOUR
T1 - Prevalence, patterns, and correlates of voluntary flunitrazepam Use.
AU - Rickert, V. I.
AU - Wiemann, C. M.
AU - Berenson, A. B.
PY - 1999/1
Y1 - 1999/1
N2 - OBJECTIVE: To determine prevalence, patterns, and correlates of voluntary flunitrazepam use in a sample of sexually active adolescent and young adult women 14 to 26 years of age. DESIGN: Cross-sectional survey. SETTING: University-based ambulatory reproductive health clinics. PATIENTS OR OTHER PARTICIPANTS: There were 904 women self-identified as white, African-American, or Mexican-American. INTERVENTIONS: None. MAIN OUTCOME MEASURE: Lifetime, frequency, patterns, and physical effects of flunitrazepam use. RESULTS: Lifetime use was reported by 5.9% (n = 53) of subjects, with frequency of use ranging from 1 to 40 times. Flunitrazepam was taken most often with alcohol (74%), and 49% took this substance with other illicit drugs. Logistic regression analyses controlling for age and race/ethnicity found that users were significantly more likely than were nonusers to report lifetime use of marijuana (odds ratio [OR] = 3.6) or LSD (OR = 5.2), having a peer or partner who used flunitrazepam (OR = 21.7), pressure to use flunitrazepam when out with friends (OR = 2.7), and a mother who had at least a high school education (OR = 2.6). Finally, 10% of voluntary users reported experiencing subsequent physical or sexual victimization. CONCLUSIONS: Voluntary use of flunitrazepam is becoming a health concern to sexually active young women who reside in the southwestern United States. Young women who have used LSD or marijuana in the past or who have a peer or partner who used this drug appear to be at the greatest risk.
AB - OBJECTIVE: To determine prevalence, patterns, and correlates of voluntary flunitrazepam use in a sample of sexually active adolescent and young adult women 14 to 26 years of age. DESIGN: Cross-sectional survey. SETTING: University-based ambulatory reproductive health clinics. PATIENTS OR OTHER PARTICIPANTS: There were 904 women self-identified as white, African-American, or Mexican-American. INTERVENTIONS: None. MAIN OUTCOME MEASURE: Lifetime, frequency, patterns, and physical effects of flunitrazepam use. RESULTS: Lifetime use was reported by 5.9% (n = 53) of subjects, with frequency of use ranging from 1 to 40 times. Flunitrazepam was taken most often with alcohol (74%), and 49% took this substance with other illicit drugs. Logistic regression analyses controlling for age and race/ethnicity found that users were significantly more likely than were nonusers to report lifetime use of marijuana (odds ratio [OR] = 3.6) or LSD (OR = 5.2), having a peer or partner who used flunitrazepam (OR = 21.7), pressure to use flunitrazepam when out with friends (OR = 2.7), and a mother who had at least a high school education (OR = 2.6). Finally, 10% of voluntary users reported experiencing subsequent physical or sexual victimization. CONCLUSIONS: Voluntary use of flunitrazepam is becoming a health concern to sexually active young women who reside in the southwestern United States. Young women who have used LSD or marijuana in the past or who have a peer or partner who used this drug appear to be at the greatest risk.
UR - http://www.scopus.com/inward/record.url?scp=0342915684&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0342915684&partnerID=8YFLogxK
U2 - 10.1542/peds.103.1.e6
DO - 10.1542/peds.103.1.e6
M3 - Article
C2 - 9917486
AN - SCOPUS:0342915684
SN - 0031-4005
VL - 103
SP - E6
JO - Pediatrics
JF - Pediatrics
IS - 1
ER -